Evaluation of gefitinib for treatment of refractory solid tumors and central nervous system malignancies in pediatric patients.
about
Recent advances on the molecular mechanisms involved in the drug resistance of cancer cells and novel targeting therapiesEpidermal growth factor receptor polymorphisms and risk for toxicity in paediatric patients treated with gefitinib.Molecular profiling of childhood cancer: Biomarkers and novel therapiesCopy number gains in EGFR and copy number losses in PTEN are common events in osteosarcoma tumors.Specific tyrosine kinase inhibitors regulate human osteosarcoma cells in vitro.Pediatric CNS tumors: current treatment and future directions.Inheritance of susceptibility to induction of nephroblastomas in the Noble rat.New approaches to pharmacotherapy of tumors of the nervous system during childhood and adolescence.Pediatric brain tumors: current treatment strategies and future therapeutic approachesPaediatric high and low grade glioma: the impact of tumour biology on current and future therapy.Phase I and pharmacokinetic study of cetuximab and irinotecan in children with refractory solid tumors: a study of the pediatric oncology experimental therapeutic investigators' consortium.Met interacts with EGFR and Ron in canine osteosarcomap53 family: Therapeutic targets in neuroblastoma.Receptor tyrosine kinases as therapeutic targets in rhabdomyosarcoma.Pediatric neuro-oncology: current status and future directions.Noscapine targets EGFR(p-Tyr1068) to suppress the proliferation and invasion of MG63 cells.Anti-angiogenesis target therapy for advanced osteosarcoma (Review).Antitumor effect in medulloblastoma cells by gefitinib: Ectopic HER2 overexpression enhances gefitinib effects in vivo.Cross-talk between Notch and EGFR signaling in human breast cancer cells.
P2860
Q33730375-3B2E54B3-2FCD-4BF3-AC42-D0EA8CBF61EAQ33996096-61D5CAB0-BC94-4CAA-8123-C2F6A419C949Q36250783-097E4D53-160E-474D-86DC-EE71D68DDEE1Q36486421-59E0E0D6-0314-43BB-B054-505A1F8AD3E0Q36803657-FB7A4AC6-546D-4601-AF06-FC26CB2D83C4Q36902043-F2EF5B23-75A4-423E-9523-9BE4973CDE0DQ37226803-87BC6747-313C-4B51-B7D8-56DFBAF71130Q37422646-697761BD-0180-42E9-BC16-CF0CA7C18A49Q37533670-ED95F63C-E527-460B-B7A6-3F7893A7F6D7Q37564201-5C5C3174-FD29-4137-8054-F2128969ACEBQ37659101-F98DDA3A-AB8C-4BB7-9A75-4888EC8E4317Q37672081-B0ED44D2-DF80-4EAA-BF8A-A9BCFFFF10B3Q37707387-DDBB817B-4404-4D9C-9562-D38B3FB5113DQ37831148-A9D8B9E4-1890-4478-A86E-CDD8AA92076FQ38035070-0943EBC1-E8D7-487D-9A62-5EFF78477AB1Q38731969-CFA9EEBB-4C9C-40D7-BF08-BD88CAE7E5C6Q39401628-43B6A6C9-1E14-4480-8CFD-A2710EB8B08DQ39912369-3BDE0878-6382-4571-98E1-ABF334D7926BQ46121027-39D27250-A42B-4519-8FCD-6796EBA596DD
P2860
Evaluation of gefitinib for treatment of refractory solid tumors and central nervous system malignancies in pediatric patients.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Evaluation of gefitinib for tr ...... nancies in pediatric patients.
@ast
Evaluation of gefitinib for tr ...... nancies in pediatric patients.
@en
type
label
Evaluation of gefitinib for tr ...... nancies in pediatric patients.
@ast
Evaluation of gefitinib for tr ...... nancies in pediatric patients.
@en
prefLabel
Evaluation of gefitinib for tr ...... nancies in pediatric patients.
@ast
Evaluation of gefitinib for tr ...... nancies in pediatric patients.
@en
P2093
P2860
P1433
P1476
Evaluation of gefitinib for tr ...... nancies in pediatric patients.
@en
P2093
Burgess B Freeman
Clinton F Stewart
J Russell Geyer
Najat C Daw
Wayne L Furman
P2860
P304
P356
10.1080/07357900600632058
P577
2006-04-01T00:00:00Z